Gufic Biosciences Limited is an India-based company engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), generic pharmaceuticals, and related services. Incorporated in July 1984, Gufic Biosciences (GBL) was initially known as Gujarat Fine Chemicals. The Gufic group's first foray was in the manufacture of various bulk drugs. Gufic has been in the pharmaceutical business since 1960, promoting and selling ethical, herbal, consumer, and bulk drugs in domestic and international markets. The company has established itself as a significant player in the pharmaceutical sector, evolving from a bulk drug manufacturer to a comprehensive pharmaceutical services provider. It later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products, and bulk drugs sold in domestic and international markets.
The Company operates through the pharmaceutical segment, with its business structure organized into several key segments catering to different therapeutic areas and market needs.
The company develops pharmaceutical formulations in various forms, including injectables, syrups, ointments, lotions, and herbal products. It serves over 15 therapeutic areas, including critical care and infertility, with a portfolio of 100+ products, 200+ SKUs, and a network of 30,000+ prescribers.
Gufic BioSciences offers pharmaceutical products under categories such as:
- Criti Care: Including Doxific, Micafung, Rabol, and Tigefic-Plus.
- Criticare Life: Including Ticofic-200 and Gufivan-500.
- Ferticare: Including Puregraf 75IU 3D, Cetrocare 0.25mg 3D, and Follicare 150IU 3D.
- Spark: Including Aznee Duo, Eclin, Flabone, Vipro M, and Zad G.
- Herbal: Including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap, and Smashit tablet.
- Aesthaderm: Including Prosil, Moiseta Face Wash, and Revanox Serum.
Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel, and RollOn. Its products under Active Pharmaceutical Ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole, and Everolimus.
Gufic BioSciences is one of the largest manufacturers of Lyophilized Injections in India, boasting a fully automated lyophilization plant. The company's manufacturing expertise extends across multiple pharmaceutical forms and technologies. It manufactures APIs and bulk drugs such as antifungals, anesthetics, immunosuppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments.
The company aims to expand into Biologicals and Immuno-Oncology. This strategic direction indicates Gufic BioSciences' commitment to advancing into higher-value therapeutic areas and cutting-edge pharmaceutical technologies. Over the past several years, the company has built a reputation for creating brands that have achieved leadership positions in their respective categories. Gufic BioSciences plans to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresees huge potential.
As of December 2024, the Market Cap was ₹3,642 Crore. More recent data from Business Standard indicates Gufic BioSciences Ltd has a market capitalization of ₹3,711 crore.
- Net Profit: ₹21.78 crore (declined 6.16% compared to ₹23.21 crore in Q2 FY24).
- Sales: ₹204.18 crore (declined 4.98% compared to ₹214.87 crore in Q2 FY24).
- EBITDA: ₹38.7 crore (registered a de-growth of 2.52% compared to ₹39.7 crore in Q2 FY24).
- EBITDA Margin: Increased to 18.95% in Q2 FY25 from 18.47% in Q2 FY24.
On a consolidated basis, Gufic BioSciences Ltd reported a profit of ₹7.72 crore on a total income of ₹205.41 crore for the quarter ended June 2024.
The Gufic BioSciences Ltd's 52-week high share price is ₹501.10, and the 52-week low share price is ₹285.00. Over the last 12 months, Gufic BioSciences Ltd's share price has moved up by 17.50% on BSE.
In the fiscal year 2020-21, Gufic Lifesciences Private Limited amalgamated with the Company, with the Scheme of Amalgamation becoming effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in the United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.
Promoter holding in Gufic BioSciences Ltd has increased to 72.51% as of March 2025 from 72.51% as of June 2024.
Gufic BioSciences represents a well-established pharmaceutical company with a diversified product portfolio spanning critical care, infertility treatments, herbal products, and consumer healthcare. The company's strong positioning in lyophilized injections, combined with its strategic expansion into biologicals and immuno-oncology, positions it for future growth in the evolving pharmaceutical landscape.
